Welcome to our dedicated page for Burning Rock Biotech SEC filings (Ticker: BNR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Burning Rock Biotech Limited (NASDAQ: BNR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Burning Rock files annual reports on Form 20-F and current reports on Form 6-K with the U.S. Securities and Exchange Commission, covering its precision oncology business based on next generation sequencing (NGS) technology.
In these filings, Burning Rock presents detailed information on its three operating segments: central laboratory business, in-hospital business and pharma research and development services. Investors can review segment revenues, gross profit, operating expenses and discussions of the company’s use of non-GAAP measures such as non-GAAP gross profit and non-GAAP gross margin, which exclude depreciation and amortization.
Form 6-K submissions often incorporate press releases by reference, including quarterly financial results, business updates and information on regulatory milestones. These may describe developments in NGS-based therapy selection testing for late-stage cancer patients, cancer early detection programs that have entered clinical validation, and global pharmaceutical services on biomarker detection and companion diagnostics development.
Through Stock Titan, users can track Burning Rock’s real-time filings as they are furnished to the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents, highlighting items such as segment performance, geographic revenue breakdowns, and updates on regulatory approvals or collaborations related to companion diagnostics. The filings page is a resource for understanding how Burning Rock describes its business model, financial condition and risk factors in official U.S. securities filings connected to BNR stock.
Burning Rock Biotech Ltd director Deng Feng filed an initial Form 3 reporting indirect holdings of the company’s Ordinary Shares. The filing shows positions held through Northern Light Venture Fund III, L.P., Northern Light Strategic Fund III, L.P., and Northern Light Partners Fund III, L.P.
These Cayman Islands partnerships are managed by Northern Light Venture Capital III, Ltd., where Deng Feng serves as director and makes investment decisions. He disclaims beneficial ownership of the reported securities for Section 16 purposes, except to the extent of any pecuniary interest.
Burning Rock Biotech Ltd director Wendy W. Hayes filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes her status as a director and indicates that no insider transactions or derivative positions are reported in this submission.
Burning Rock Biotech Ltd director Han Yusheng has filed an initial ownership report showing a substantial equity stake and multiple option awards. The filing lists direct ownership of 17,357,806 Ordinary Shares.
Han also holds several option grants over Ordinary Shares. These include 1,413,063 and 2,119,595 options with a $3.33 exercise price that vest only if the company’s valuation reaches $4 billion within seven years of the September 26, 2022 grant date and employment conditions are met. Additional grants of 706,532 and 1,059,797 options at the same exercise price require a $10 billion valuation target plus similar service conditions.
Further grants on April 30, 2023, April 30, 2024 and April 30, 2025 cover 236,023, 86,000 and 116,000 options at a $0.0002 exercise price, vesting in stages from 2025 through 2029 based on continued employment and minimum performance ratings. Each option gives the right to receive one Ordinary Share upon exercise.
Burning Rock Biotech Ltd director Zhang Zhihong filed an initial ownership report showing direct holdings of 1,061,990 Ordinary Shares and multiple option awards. These include options over 78,504 and 117,755 Ordinary Shares at an exercise price of $3.33 expiring on September 26, 2032, plus additional options over 51,469, 41,000, and 56,000 shares at an exercise price of $0.0002 expiring between 2033 and 2035. Several grants vest only if Burning Rock’s valuation and the director’s employment and performance conditions are met.
Burning Rock Biotech Ltd filed an initial Form 3 for Hu Xiaozhi, a Senior Director in Finance, detailing existing stock option holdings rather than new market trades. The options give the right to receive one ordinary share per option at exercise prices as low as $0.0002 and $3.33.
The footnotes show these awards vest only if strict conditions are met, including continued employment, annual performance ratings of at least 3.3%, and ambitious company valuation targets of $2 billion, $4 billion, or $10 billion within specified five- or seven-year periods from each grant date.
Burning Rock Biotech Ltd director Xu Licen Lisa filed an initial Form 3 reporting her ownership in the company. The filing shows she directly holds 22,718 Ordinary Shares following the reported position. This is a disclosure of existing holdings and does not reflect any recent share purchase or sale activity.
Burning Rock Biotech reported much narrower losses for 2025 as efficiency improved. Full-year revenue reached RMB539.6 million, up 4.6% from 2024, while gross margin rose to 74.7% from 70.3% as cost of revenues fell 10.9%.
Operating expenses dropped sharply to RMB457.8 million from RMB720.0 million, helped by budget controls and headcount reductions, reducing net loss to RMB55.3 million from RMB346.6 million. In the fourth quarter, revenue was RMB126.3 million, gross margin climbed to 78.0%, and net loss shrank to RMB15.4 million from RMB81.3 million. Cash, cash equivalents and restricted cash totaled RMB481.1 million as of December 31, 2025.
Burning Rock Biotech Limited has furnished a Form 6-K as a foreign private issuer to provide a press release, filed as Exhibit 99.1. The company states that Exhibit 99.1, excluding the sections and table relating to non-GAAP measures, is incorporated by reference into its effective Form F-3 registration statement.